Javier Cerrillo-Molina

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Journal: Expert opinion on biological therapy

Published: August 29, 2026

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Journal: BMC cancer

Published: June 13, 2026

From Cystectomy to Conservation: Can Perioperative Enfortumab Vedotin Plus Pembrolizumab and Immuno-Radiotherapy Redefine the Standard of Care in Muscle-Invasive Bladder Cancer?

From Cystectomy to Conservation: Can Perioperative Enfortumab Vedotin Plus Pembrolizumab and Immuno-Radiotherapy Redefine the Standard of Care in Muscle-Invasive Bladder Cancer?

Journal: The Journal of urology

Published: April 28, 2026

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

Journal: ESMO open

Published: April 21, 2026

Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.

Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.

Journal: European urology

Published: March 30, 2026

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Journal: Investigational new drugs

Published: March 12, 2026

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Journal: Targeted oncology

Published: February 20, 2026

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Journal: Frontiers in immunology

Published: February 05, 2026

Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.

Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.

Journal: Expert opinion on pharmacotherapy

Published: February 04, 2026

Showing 1-12 of 116

Last Updated: 09/26/2026